Breaking News

Kemwell Appoints President

By Kristin Brooks | March 24, 2014

Advant brings 20 years of industry experience

Siddharth J. Advant, Ph.D. has been appointed president of biopharmaceutical services at Kemwell Biopharma. Anurag Bagaria, chairman and managing director, said, “Dr. Advant exemplifies Kemwell’s commitment to delivering high performance to its customers. He is a proven leader with over 20 years of experience in the biopharmaceutical industry. His extensive experience in CMC development and commercialization will help Kemwell grow its contract biotech business. As a member of Kemwell’s core committee for strategic growth, Dr. Advant will lead a team of professionals charged with developing and delivering high-quality services in the most efficient manner possible to biopharmaceutical companies globally.”
Dr. Advant brings 20 years of industry experience having held a variety of leadership positions across the biopharma industry. He joins the company from ImClone Systems, a subsidiary of Eli Lilly & Co., where he was associate vice president of CMC project management. Prior to ImClone, Dr. Advant was the head of Tunnell Consulting’s West Coast Office. He also served as director for Diosynth Biotechnology, heading project management and business alliances, technology transfer and clinical operations, and pharmaceutical sciences and stability, and worked as a scientist in the pharmaceutical development division at Protein Design Labs, Inc.
  • Packaging Equipment Technology Preview

    Packaging Equipment Technology Preview

    February 15, 2017
    Today’s complex drug products present challenges; the latest equipment capabilities help overcome them

  • The Good, the Bad, and the Donald

    The Good, the Bad, and the Donald

    January 31, 2017
    Orphan drugs, CMO continuous manufacturing and developing world sales offer biggest revenue opportunities

  • Predictive Analytics and the Future of RBM

    Rajneesh Patil, Senior Director, RBM and Analytics, QuintilesIMS||January 23, 2017
    How advances in Risk-Based Monitoring will enable a more proactive approach to identify and mitigate potential risks